PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 4.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,958,479 | +37.8% | 4,406,252 | 0.0% | 1.42% | +35.0% |
| Q2 2023 | $66,710,655 | +242.2% | 4,406,252 | +82.1% | 1.05% | +365.0% |
| Q1 2023 | $19,494,349 | -28.4% | 2,420,155 | 0.0% | 0.23% | -37.2% |
| Q4 2022 | $27,226,744 | +46.7% | 2,420,155 | 0.0% | 0.36% | +64.4% |
| Q3 2022 | $18,563,000 | -65.3% | 2,420,155 | 0.0% | 0.22% | -68.6% |
| Q2 2022 | $53,485,000 | +21.9% | 2,420,155 | 0.0% | 0.70% | +74.1% |
| Q1 2022 | $43,890,000 | +26.0% | 2,420,155 | 0.0% | 0.40% | +49.1% |
| Q4 2021 | $34,826,000 | -18.8% | 2,420,155 | 0.0% | 0.27% | +7.2% |
| Q3 2021 | $42,909,000 | -4.8% | 2,420,155 | 0.0% | 0.25% | -21.3% |
| Q2 2021 | $45,087,000 | -33.4% | 2,420,155 | 0.0% | 0.32% | -59.8% |
| Q1 2021 | $67,716,000 | – | 2,420,155 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,246,926 | $26,153,989 | 13.57% |
| venBio Partners LLC | 2,278,575 | $18,353,922 | 10.17% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $25,620 | 3.20% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 559,387 | $4,505,862 | 1.86% |
| 5AM Venture Management, LLC | 587,600 | $4,733,118 | 1.21% |
| Sio Capital Management, LLC | 228,385 | $1,839,641 | 0.91% |
| Novo Holdings A/S | 1,329,325 | $10,714,360 | 0.71% |
| Cormorant Asset Management, LP | 816,460 | $6,577 | 0.43% |
| Soleus Capital Management, L.P. | 336,900 | $2,713,730 | 0.28% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $19,494,349 | 0.23% |